{
    "clinical_study": {
        "@rank": "50381", 
        "acronym": "GOLDEN 6", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo bid"
            }, 
            {
                "arm_group_label": "SUN-101 3 mcg", 
                "arm_group_type": "Experimental", 
                "description": "SUN-101 3 mcg bid"
            }, 
            {
                "arm_group_label": "SUN-101 6.25 mcg", 
                "arm_group_type": "Experimental", 
                "description": "SUN-101 6.25 mcg bid"
            }, 
            {
                "arm_group_label": "SUN-101 12.5 mcg", 
                "arm_group_type": "Experimental", 
                "description": "SUN-101 12.5 mcg bid"
            }, 
            {
                "arm_group_label": "SUN-101 50 mcg", 
                "arm_group_type": "Experimental", 
                "description": "SUN-101 50 mcg bid"
            }, 
            {
                "arm_group_label": "Aclidinium 400 mcg", 
                "arm_group_type": "Active Comparator", 
                "description": "Aclidinium 400 mcg bid"
            }
        ], 
        "brief_summary": {
            "textblock": "Study for subjects 40 to 65 years-old with a diagnosis of moderate to severe COPD.\n      Aclidinium bromide 400 mcg 2x a day will be given as an active comparator."
        }, 
        "brief_title": "A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": "COPD", 
        "condition_browse": {
            "mesh_term": [
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, six-way crossover study to determine the efficacy and dose-response\n      profile of SUN101. The study population will consist of subjects 40 to 65 years-old\n      (inclusive), with a diagnosis of moderate to severe COPD. Aclidinium bromide 400 mcg bid\n      will be given as an active comparator. The study will be double-blind for SUN-101 and\n      placebo and will be open-label for aclidinium."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female patients 40 to 65 years-old, inclusive.\n\n          2. A clinical diagnosis of moderate to severe COPD according to the GOLD 2011\n             guidelines.\n\n          3. Current smokers or ex-smokers with at least 10 pack year smoking history (eg, at\n             least 1 pack/day for 10 years, or equivalent).\n\n          4. Post bronchodilator (following inhalation of ipratropium bromide) FEV1 \u2265 40% and \u2264\n             70% of predicted normal during Screening.\n\n          5. Post bronchodilator (following inhalation of ipratropium bromide) FEV1/FVC ratio \u2264\n             0.70 during Screening.\n\n          6. Post bronchodilator (following inhalation of ipratropium bromide) improvement in FEV1\n             \u2265 12% and \u2265 100 mL during Screening.\n\n          7. Ability to perform reproducible spirometry according to the American Thoracic Society\n             (ATS) and European Respiratory Society (ERS) guidelines (2005).\n\n          8. Female of child bearing potential (only) must have a negative serum pregnancy test at\n             Screening and be neither breastfeeding nor intending to become pregnant during study\n             participation. Females of childbearing potential must be instructed to and agree to\n             avoid pregnancy during the study. Female subjects of child bearing potential must use\n             an adequate method of birth control from Screening until 30 days after receiving\n             study drug and use contraception in addition to their partners using a barrier\n             method. Acceptable forms of contraception are as follows:\n\n               -  Abstinence\n\n               -  Barrier methods: condoms, diaphragms, cervical caps; with a spermicide foam,\n                  gel, film, cream or suppository;\n\n               -  Oral contraceptives\n\n               -  Non hormone containing intrauterine methods: intrauterine devices or systems.\n\n          9. Willing and able to remain at the study site for at least 24 hours at Day 7 of each\n             Treatment Period.\n\n         10. Willing and able to attend all study visits and adhere to all study\n             assessments/procedures.\n\n         11. Willing and able to provide written informed consent\n\n        Exclusion Criteria:\n\n          1. Current evidence or recent history of any clinically significant and unstable disease\n             (other than COPD) or abnormality in the opinion of the Investigator that would put\n             the subject at risk or which would compromise the quality of the study data;\n             including but not limited to cardiovascular disease, myocardial infarction, cardiac\n             failure, uncontrolled hypertension, life threatening arrhythmias, uncontrolled\n             diabetes, neurologic or neuromuscular disease, liver disease, gastrointestinal\n             disease or electrolyte abnormalities.\n\n          2. Current evidence or history of a clinically significant abnormality of cardiac rhythm\n             and/or conduction including Holter monitoring prior to randomization.\n\n          3. Primary diagnosis of asthma.\n\n          4. History of malignancy of any organ system, treated or untreated within the past 5\n             years, with the exception of localized basal cell carcinoma of the skin.\n\n          5. Recent history of COPD exacerbation requiring hospitalization or need for increased\n             treatments for COPD within 6 weeks prior to Screening.\n\n          6. Use of daily oxygen therapy > 10 hours per day.\n\n          7. Use of systemic steroids within 3 months prior to Screening.\n\n          8. Respiratory tract infection within 6 weeks prior to or during Screening.\n\n          9. History of tuberculosis, bronchiectasis or other non-specific pulmonary disease.\n\n         10. History of urinary retention or bladder neck obstruction type symptoms.\n\n         11. History of narrow angle glaucoma.\n\n         12. Prolonged QTcF interval (males > 450 msec and females >470 msec) during Screening, or\n             history of long QT syndrome.\n\n         13. Recent history (previous 12 months) of excessive use or abuse of alcohol or\n             narcotic/illegal drugs.\n\n         14. History of hypersensitivity or intolerance to aerosol medications, beta-2 agonists,\n             or anticholinergics.\n\n         15. Participation in another investigational drug study where drug was received within 30\n             days prior to Screening, or current participation in another investigational drug\n             trial.\n\n         16. Subject is a staff member of the clinical site or a relative of a clinical site staff\n             member."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "96", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02038829", 
            "org_study_id": "SUN101-201"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "SUN-101 3 mcg", 
                "description": "SUN-101 3 mcg bid", 
                "intervention_name": "SUN101 3 mcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "SUN-101 6.25 mcg", 
                "description": "SUN-101 6.25 mcg bid", 
                "intervention_name": "SUN-101 6.25 mcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "SUN-101 12.5 mcg", 
                "description": "SUN-101 12.5 mcg bid", 
                "intervention_name": "SUN-101 12.5 mcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "SUN-101 50 mcg", 
                "description": "SUN-101 50 mcg bid", 
                "intervention_name": "SUN-101 50 mcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Aclidinium 400 mcg", 
                "description": "Aclidinium 400 mcg bid", 
                "intervention_name": "Aclidinium", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "COPD", 
        "lastchanged_date": "May 15, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Clearwater", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33765"
                    }, 
                    "name": "Clinical Research of West Florida, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlotte", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28207"
                    }, 
                    "name": "American Health Research, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27607"
                    }, 
                    "name": "North Carolina Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Medford", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97504"
                    }, 
                    "name": "Clinical Research Institute of Southern Oregon, PC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Easley", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29640"
                    }, 
                    "name": "Palmetto Medical Research Associates, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenville", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29615"
                    }, 
                    "name": "Upstate Pharmaceutical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenville", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29615"
                    }, 
                    "name": "Greenville Pharmaceutical Research, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spartanburg", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29303"
                    }, 
                    "name": "S. Carolina"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spartanburg", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29303"
                    }, 
                    "name": "Spartanburg Medical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Union", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29379"
                    }, 
                    "name": "CU Pharmaceutical Research"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD: GOLDEN 6 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)", 
        "overall_official": {
            "affiliation": "Sunovion", 
            "last_name": "SUN101 Medical Director, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in trough FEV1 at Treatment Visit Day 7 compared to placebo.", 
            "safety_issue": "No", 
            "time_frame": "Day 7"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02038829"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Standardized change from baseline in FEV1 AUC(0-12hours)", 
                "safety_issue": "No", 
                "time_frame": "Day 7"
            }, 
            {
                "measure": "Number and percentage of subjects with treatment-emergent adverse events (overall and by treatment)", 
                "safety_issue": "No", 
                "time_frame": "Over 7 days"
            }
        ], 
        "source": "Sunovion Respiratory Development Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sunovion Respiratory Development Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}